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Newborn screening for cystic ﬁ brosis
Carlo Castellani, John Massie, Marci Sontag, Kevin W Southern
Since the late 1970s when the potential of the immunoreactive trypsinogen assay for early identiﬁ cation of infants 
with cystic ﬁ brosis was ﬁ rst recognised, the performance of newborn blood spot screening (NBS) has been continually 
assessed and its use has gradually expanded. NBS for cystic ﬁ brosis is a cost-eﬀ ective strategy and, if standards of care 
are fully implemented and robust management pathways are in place, has a positive eﬀ ect on clinical outcomes. In 
the past decade, NBS has undergone rapid expansion and an unprecedented number of infants with cystic ﬁ brosis 
have access to early diagnosis and care. Cystic ﬁ brosis NBS has now moved on from the development phase and is 
entering an era of consolidation. In the future, research should focus on the rationalisation and optimisation of 
existing programmes, with particular attention to bioethical implications such as unwanted detection of carriers and 
inconclusive diagnoses.
Introduction
A proactive multidisciplinary approach has long been 
promoted for the care of people with cystic ﬁ brosis.1,2 In 
the past three decades, increasing evidence that well-
nourished and active patients enjoy a better quality of 
life, respiratory function, and survival has emerged to 
support this strategy.3,4 Early researchers in cystic 
ﬁ brosis believed newborn blood spot screening (NBS) 
was a valid strategy to help achieve these goals. The 
characterisation of the immunoreactive trypsinogen 
(IRT) assay in 1979 provided laboratories with a potential 
screening test to identify infants with cystic ﬁ brosis in 
the ﬁ rst weeks of life, often before they presented with 
clinical signs.5 The IRT assay seemed to have better 
sensitivity than other screening tests that had previously 
been used to identify infants with cystic ﬁ brosis (eg, 
measuring meconium albumin or lactase levels)6,7 and 
was included in the NBS schedule already established 
for other diseases such as phenylketonuria. However, 
concerns were raised that screening of infants for cystic 
ﬁ brosis might not have suﬃ  cient eﬀ ect on clinical 
outcomes to meet the criteria required to advocate 
universal screening. This concern prompted a call for 
evidence to show that NBS was beneﬁ cial for children 
with cystic ﬁ brosis.
Previous research
Clinical trials and epidemiological studies
Two pseudo-randomised clinical trials were initiated in 
the 1980s. A trial in the UK screened newborn babies 
for cystic ﬁ brosis on alternate weeks.8 After 4 years, no 
substantial diﬀ erences were reported in the nutritional 
or respiratory outcomes of 58 infants with cystic ﬁ brosis 
identiﬁ ed by screening compared with 44 children 
diagnosed clinically.8 Simultaneously, in a trial in 
Wisconsin, a substantial nutritional beneﬁ t was noted 
in the cohort of 56 infants who were diagnosed early 
through screening compared with the 40 infants in the 
cohort diagnosed clinically.9 Furthermore, evidence of 
increased airway damage on chest radiographs was 
reported in the screened cohort, possibly as a result of 
earlier Pseudomonas infection.10 Issues with the clinical 
management of these infants were described for both 
clinical trials, notably infrequent visits to a cystic 
ﬁ brosis centre and suboptimum segregation policies 
that might have had an adverse eﬀ ect on clinical 
outcomes.
Despite the scarcity of deﬁ nitive evidence of improved 
outcome from these clinical trials, NBS for cystic 
ﬁ brosis has expanded worldwide, particularly in the 
past decade.11 This expansion was based on evidence 
from epidemiological sources, including patient 
registries, which provided information on health-care 
costs and longer term outcomes.12,13 
Long-term results from cohort studies
A major diﬃ  culty in evaluation of the clinical eﬀ ects of 
cystic ﬁ brosis NBS is that positive outcomes can take 
many years to become apparent. Compelling evidence 
has come from the long-term follow-up of children 
enrolled in the Sydney cohort study.14 Data available for 
the progress of these patients in their third decade of life 
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showed that those diagnosed after the introduction of 
NBS have improved survival compared with those 
diagnosed clinically. A historical cohort study is not an 
ideal design to compare two public health strategies; 
however, the length of this study mitigates these 
deﬁ ciencies and the results provide good evidence that 
earlier diagnosis from NBS might have a notable eﬀ ect 
on wellbeing and survival in adult life.
Cost-eﬀ ectiveness studies
Beyond the existing NBS infrastructure (distribution and 
timely collection of screening cards), cystic ﬁ brosis 
newborn screening needs additional expenditure for 
analysis (eg, IRT and DNA), maintenance of laboratory 
standards, supervision of reports, implementation of 
systems to ensure appropriate handling of positive 
results, and costs associated with the assessment and 
processing of false-positive results.
Whereas in the early years of cystic ﬁ brosis NBS, 
decisions to screen were mainly based on clinical and 
social factors, subsequently more formal cost-eﬀ ectiveness 
analysis of newborn screening for cystic ﬁ brosis has 
become a key element of the assessment of this public 
health intervention.
A decision-tree analysis suggested that NBS was an 
expensive method of diagnosis, but acknowledged that it 
could be cost eﬀ ective if it delayed the onset of symptoms.15 
This suggestion is supported by results from studies 
showing that the cost of care of patients with cystic 
ﬁ brosis was substantially lower if the disease was detected 
early through screening.16 In a UK Registry study that 
compared 184 infants diagnosed by NBS with 950 infants 
diagnosed clinically, substantial savings were reported in 
drug utilisation costs that oﬀ set the additional costs of 
adding cystic ﬁ brosis screening to existing NBS 
programmes.17 A Dutch study comparing diﬀ erent 
screening strategies based on a theoretical birth cohort of 
200 000 infants reported savings in all models of NBS.18
The IRT assay
The IRT assay provides the framework on which all NBS 
for cystic ﬁ brosis is currently based.19 Elevated IRT is 
thought to be related to the pancreatic damage often 
present in infants with cystic ﬁ brosis, but it can also identify 
infants with a milder, pancreatic suﬃ  cient phenotype and 
some carriers.20 Automated immunoassays enable large 
numbers of samples to be processed as part of a NBS 
programme.21 A better quality of dried blood spot sample is 
needed for the IRT assay compared with other analytes 
used for NBS. Thus, inclusion of cystic ﬁ brosis into the 
panel of NBS disorders necessitates additional support and 
training for health-care workers who obtain the blood spot 
sample and, invariably, an increased number of repeat 
sample requests. However, in a well-organised screening 
laboratory and public health service, incorporation of cystic 
ﬁ brosis into the NBS programme should be feasible.21
Other technical issues make interpretation of IRT 
assay results challenging, most notably variability 
between batches of reagents used for the assay that aﬀ ect 
the IRT values and an apparent reduction in overall IRT 
values reported during hot seasons, possibly resulting 
from some degradation of the protein as the sample is 
transferred to the laboratory.20 Some screening 
laboratories have advocated the continuous monitoring 
of IRT values and altering the cutoﬀ  accordingly to 
achieve a predetermined percentage of infants referred 
(a ﬂ oating cutoﬀ ).20
Strategies to reduce false-negative and 
false-positive rates
Similar to most public health interventions, a ﬂ awless 
cystic ﬁ brosis NBS programme is unrealistic if not 
unachievable. Accurate strategic choices might optimise 
the eﬀ ectiveness of cystic ﬁ brosis NBS, however, some 
false negatives and false positives and infants in whom 
cystic ﬁ brosis cannot be conﬁ rmed or excluded are 
inherent in screening programmes. Tolerance of a few 
missed cases might be instrumental in limiting 
unwanted eﬀ ects of NBS, such as inconclusive cases. 
Table 1 shows how sensitivity, speciﬁ city, and positive 
predictive value (PPV; the ratio between true positives 
and all positive test results) of cystic ﬁ brosis NBS 
strategies are deﬁ ned.
Improving speciﬁ city
Measurement of IRT during the ﬁ rst week of life (IRT-1) 
provides a sensitive test to identify infants with cystic 
ﬁ brosis; however, the test is not speciﬁ c. To limit the 
number of false positives and achieve an acceptable 
combination of sensitivity and speciﬁ city, a range of 
diﬀ erent second-tier and sometimes third-tier tests are 
used in infants with a raised IRT-1 (table 2).
Aﬀ ected Not aﬀ ected
NBS positive A: true positive B: false positive
NBS negative C: false negative D: true negative
Sensitivity=A / (A + C). Speciﬁ city=D / (B + D). Positive predicitve value=A / (A + B). 
NBS=newborn blood spot screening.
Table 1: Deﬁ nitions of sensitivity, speciﬁ city, and positive predictive 
value of NBS strategies for cystic ﬁ brosis 
Strategy 1 Strategy 2 Strategy 3 Strategy 4 Strategy 5 Strategy 6 Strategy 7
1° tier IRT1 IRT1 IRT1 IRT1 IRT1 IRT1 IRT1
2° tier IRT2 DNA DNA IRT2 DNA PAP PAP
3° tier ·· ·· EGA DNA IRT2 DNA DNA
4° tier ·· ·· ·· ·· ·· ·· EGA
IRT1=immunoreactive trypsinogen assay at birth. IRT2=immunoreactive trypsinogen assay at day 21. DNA=panel of 
cystic ﬁ brosis transmembrane conductance regulator (CFTR) mutations. EGA=extended genetic analysis by 
sequencing. PAP=pancreatitis associated protein. NBS=newborn blood spot screening. All strategies select 
NBS-positive infants. Conﬁ rmation or exclusion of cystic ﬁ brosis diagnosis is obtained by sweat test. 
Table 2: Most frequently used NBS strategies for cystic ﬁ brosis 
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The second-tier test used in early NBS programmes 
was a repeat IRT measurement from a second sample 
taken at day 10–21 of life (IRT-2). IRT values decrease in 
infants without cystic ﬁ brosis over the ﬁ rst 4 weeks of 
life, but remain high in those with cystic ﬁ brosis.22 The 
IRT/IRT protocol improves PPV by reducing the number 
of infants that are referred for a sweat test. This strategy 
depends on health resources being available to reliably 
obtain a second sample for IRT measurement.
Identiﬁ cation of the cystic ﬁ brosis transmembrane 
conductance regulator (CFTR) gene provided an 
alternative second-tier strategy. The same dried blood 
spot sample obtained for IRT-1 measurement could be 
analysed for CFTR mutations. Initially, analysis was only 
for phe508del (c.1521_1523delCTT), the most common 
mutation associated with cystic ﬁ brosis; however, larger 
panels incorporating more mutations have been used as 
the technology has advanced.20,23,24 An IRT/DNA protocol 
has the advantage of removing the need for a second 
sample, improving the timeliness of the diagnosis. For 
infants carrying two mutations included in the panel, the 
use of an IRT/DNA protocol can reduce time to diagnosis 
substantially, in some cases to less than 14 days of age.25
Improving sensitivity
Although the IRT assay is a valid instrument for NBS, 
even the most eﬀ ective programmes will miss cases. By 
far the most common cause of an aﬀ ected but undetected 
case is that the IRT-1 value falls below the cutoﬀ . 
Reducing the IRT-1 cutoﬀ  is the most straightforward 
way of improving sensitivity.21 However, even a small 
reduction in the IRT-1 cutoﬀ  will have a substantial eﬀ ect 
on PPV, with an increase in the number of infants 
requiring referral for diagnostic assessment and a sweat 
test.
Furthermore, sensitivity might be aﬀ ected by the large 
number of CFTR mutations that exist (often at very low 
population frequencies), with the possibility of a missed 
mutation being a feature of IRT/DNA protocols. To 
address this issue, genetic analysis included in the NBS 
protocol can be adapted in two ways: ﬁ rst, DNA panels 
could be used to identify larger numbers of mutations; 
and second, large areas of the CFTR gene could be 
sequenced. Using a DNA panel that resembles the DNA 
of the population being screened is good practice but, 
irrespective of size, the panel will always miss rare 
mutations. Sequencing the CFTR gene, which is faster 
and less expensive owing to the introduction of next-
generation sequencing technologies,26 could help 
eliminate this issue. However, sequencing can lead to 
increased diagnostic uncertainty with the identiﬁ cation 
of mutations with unclear phenotypic outcomes.
A widely applied strategy to avoid missed cases is to 
further test very high IRT-1 results, irrespective of the 
result of the DNA testing. This strategy is often referred 
to as safety net, failsafe, or ultra-high IRT. Several 
diﬀ erent protocols exist, including referral straight to 
sweat testing or measurement of a second IRT at day 21 
of age.21,24,27–29 The advantage of incorporating such a 
strategy is that it compensates for discrimination against 
ethnic populations with rarer CFTR mutations not 
included on a typical screening panel. One concern is 
that the strategy generally involves a substantial number 
of diagnostic assessments for recognition of a small 
number of infants with cystic ﬁ brosis. This situation is 
exacerbated by raised IRT levels in infants born 
prematurely, neonates that are unwell, and neonates with 
a chromosomal abnormality.30,31 The use of a safety net 
strategy is debated and programmes should carefully 
monitor its performance.
When mutation frequencies in the screened population 
are unknown or the use of genetic analysis is restricted, 
measuring pancreatitis associated protein (PAP) in 
addition to IRT32,33 might be an option. IRT/PAP can 
achieve acceptable sensitivity, but the PPV is reduced 
compared with IRT/DNA.34,35 This reduction in PPV 
could be nulliﬁ ed by a multi-tier protocol that uses a 
combination of IRT, PAP, and selected plus expanded 
genetic analysis. In the CHOPIN study,32 this combination 
resulted in improved PPV compared with a strategy in 
which only IRT/PAP was used.
Irrespective of the protocol used, a positive NBS test for 
cystic ﬁ brosis needs careful clinical evaluation including 
a sweat test to provide a deﬁ nitive diagnosis or, 
occasionally, to refute it. Although outside the scope of 
this Review, the importance of standardisation and 
quality monitoring of sweat chloride testing cannot be 
overemphasised. Maintaining a high-quality sweat test 
service is a key factor aﬀ ecting the eﬀ ectiveness of NBS 
for cystic ﬁ brosis.
Byproducts of cystic ﬁ brosis NBS
Carriers
Genetic analysis is considered inappropriate in children, 
unless it has health advantages. This is the case for 
cystic ﬁ brosis NBS, in which the inclusion of mutation 
analysis usually improves the performance of the 
protocol. Inevitably, some infants who have a normal 
sweat test will have one CFTR mutation detected. These 
children are carriers, a widely recognised incidental 
ﬁ nding for programmes that include mutation analysis. 
Reports suggest that the rate of carrier recognition is 
higher than expected in view of the frequency of CFTR 
mutations in the population screened. For example, in 
New South Wales, Australia,36 the rate of carriers was 
1·8 times the expected frequency. Similar values were 
reported in Victoria (Australia), Wisconsin (USA), and 
Italy.36–39 The cause of the high carrier rate has never 
been clearly explained, but is probably related to the 
eﬀ ect of the CFTR mutation on pancreatic electrolyte 
secretion. This alteration might aﬀ ect trypsinogen 
release and skew the distribution of IRT in carriers 
above the cutoﬀ  used for the whole population.40 
Evidence that the CFTR mutation aﬀ ects pancreatic 
4 www.thelancet.com/respiratory   Published online April 1, 2016   http://dx.doi.org/10.1016/S2213-2600(16)00053-9
Review
function is indirectly supported by the increased 
frequency of carriers in individuals with idiopathic 
chronic pancreatitis.41
Carrier detection is generally considered to be an 
unwanted byproduct of screening. Thus, antenatal 
information to parents should clearly state that NBS will 
not only detect infants with cystic ﬁ brosis, but also some 
carriers. Most centres advocate disclosure of carriers to 
help with genetic counselling and provide couples with 
information on the potential risk of cystic ﬁ brosis for 
future pregnancies, and likewise the risk for pregnancies 
of the index cases when they are older.42 Furthermore, 
genetic counselling can result in cascade family testing 
that, in turn, gives relatives who are at increased risk of 
being carriers a choice of whether to be tested or not.43
Discovering their carrier status before their legal 
majority does not seem to negatively aﬀ ect children. 
Furthermore, no substantial issues with the perception 
of vulnerability of carriers have been identiﬁ ed. However, 
one study identiﬁ ed that up to 18% of parents of carriers 
detected by NBS had some level of anxiety about the 
health of their child up to 4 years after screening.44,45 
Solutions to the dilemma of unwanted carrier detection 
include using alternative screening strategies that avoid 
or minimise CFTR mutation analysis (table 2), but this 
usually results in reduced sensitivity and speciﬁ city.
Inconclusive diagnosis
Although infants with cystic ﬁ brosis beneﬁ t from early 
diagnosis by NBS, the identiﬁ cation of newborn babies 
who have a positive screening result but an inconclusive 
diagnosis is a drawback of NBS. For most of these 
infants, the positive result has no long-term clinical 
signiﬁ cance. These infants might have ambiguous sweat 
chloride levels or normal sweat test values and genotypes 
including mutations with unclear clinical liability. With 
the development of the CFTR2 project,46 an increasing 
number of such mutations might be reclassiﬁ ed as cystic 
ﬁ brosis causing or non-cystic ﬁ brosis causing, but 
arguably there will always be mutations that do not have 
a clear phenotypic characterisation.
The diagnosis of some carriers detected by NBS might 
be inconclusive when subsequent genetic testing 
identiﬁ es a second mutation with unknown or variable 
phenotypic outcomes.47,48
New diagnostic designations for infants with an inconclusive 
diagnosis after NBS
Two independent recommendations were proposed for 
the classiﬁ cation and management of infants with an 
unclear diagnosis after cystic ﬁ brosis NBS. These two 
exercises were undertaken in parallel and advocate a 
similar management approach for these infants; 
however, two diﬀ erent designation terms were suggested: 
CF transmembrane conductance regulator-related 
metabolic syndrome (CRMS) in the USA and cystic 
ﬁ brosis screen-positive, inconclusive diagnosis (CFSPID) 
Figure 1: Expansion of cystic ﬁ brosis NBS programmes in Europe
Countries with regional cystic ﬁbrosis
newborn blood spot screening programmes
Countries with national cystic ﬁbrosis
newborn blood spot screening programmes
Countries considering implementation of 
cystic ﬁbrosis newborn blood spot
screening programmes
2000
2015
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in Europe. CRMS/CFSPID infants are deﬁ ned by high 
IRT at birth plus an equivocal sweat chloride 
concentration and fewer than two mutations of the CFTR 
gene that are known to be associated with cystic ﬁ brosis. 
Some infants might have two CFTR mutations, one of 
which might be of variable clinical signiﬁ cance, with a 
sweat chloride concentration <30 mmol/L.46,49,50
Varying frequency of CRMS/CFSPID and screening algorithms
All NBS programmes for cystic ﬁ brosis can result in the 
identiﬁ cation of infants with CRMS/CFSPID, including 
IRT/IRT, but the frequency has increased as protocols 
incorporate more detailed DNA analysis and 
sequencing. Some programmes with an IRT/DNA 
algorithm have reported the identiﬁ cation of one 
newborn baby with unclear diagnosis for every two with 
cystic ﬁ brosis.51,52 The ﬁ rst algorithm to use extended 
gene sequencing was an attempt to improve PPV in the 
ethnically diverse population of California.53 Samples 
from infants with one mutation on a limited DNA panel 
were sent for extended gene sequencing. This algorithm 
resulted in the identiﬁ cation of two mutations known to 
be disease causing on the ﬁ rst mutation panel in 52% 
(138 of 266) of all cystic ﬁ brosis infants diagnosed, and 
an additional 41% (110 of 266) after the sequencing step. 
The algorithm identiﬁ ed CRMS in 279 infants, which is 
more than those diagnosed with cystic ﬁ brosis by NBS.53
Clinical outcome of newborn babies with an inconclusive diagnosis
The outcome for infants with CRMS/CFSPID is not well 
characterised, particularly for those with no apparent 
clinical sequelae. Long-term ﬁ gures on CRMS/CFSPID 
infants might be biased towards symptomatic children 
and prone to loss to follow up, since families with a well 
infant can disengage from clinical contact. Data available 
at present suggest that children with CRMS/CFSPID 
might have higher than expected frequencies of 
respiratory pathogens associated with cystic ﬁ brosis, such 
as Pseudomonas aeruginosa or Staphylococcus aureus.40,52,54 It 
remains unclear if this is the result of more frequent 
culturing, or an indication of the underlying prevalence 
of these bacteria in the non-cystic ﬁ brosis population, 
particularly in the case of Staphylococcus aureus infection.
The number of CRMS/CFSPID infants that are 
subsequently diagnosed with cystic ﬁ brosis is unclear; 
currently available evidence suggests that up to 3 years of 
age, roughly 1 in 10 infants is diagnosed with cystic 
ﬁ brosis.51,54 A substantial number of the mutations 
recognised in CRMS/CFSPID infants are well 
characterised in adults, often in the context of late 
diagnosis or milder disease presentations. Some adults 
have a condition called CFTR-related disorder, which is 
characterised by single organ disease (generally congenital 
bilateral absence of the vas deferens) and a normal sweat 
test.55 Infants with CRMS/CFSPID might have an 
increased risk of a CFTR-related disorder in adult life. 
Comprehensive genotyping and long-term data collection 
are important, particularly in cystic ﬁ brosis registries as a 
subgroup undergoing separate analyses. Although 
predicting individual correlations between genotype and 
phenotype evolution might prove unrealistic, long-term 
reviews will improve our understanding of the eﬀ ect of 
inconclusive NBS diagnoses on public health.
Clinical guidelines for the care of CRMS/CFSPID 
infants recommend regular although infrequent clinic 
visits and repeating the sweat test at 6 months and 2 years 
of age.50 Families should be aware of potential health 
problems and the importance of maintaining a healthy 
lifestyle, even if they are discharged from the cystic 
ﬁ brosis clinic.56
Research needed
How many, and which, infants with inconclusive diagnoses detected through 
cystic ﬁ brosis NBS will eventually develop clinically relevant manifestations 
related to CFTR?
Long-term follow-up studies in CRMS/CFSPID children
Is the integration of the PAP assay into cystic ﬁ brosis NBS programmes 
compatible with a reduction of some unwanted eﬀ ects (eg, carrier detection 
and inconclusive diagnoses) while maintaining acceptable performance of the 
programme?
Comparative longitudinal studies 
Can the sensitivity (inclusion of cystic ﬁ brosis-causing mutations only) and 
speciﬁ city (exclusion of non-cystic ﬁ brosis-causing mutations) of genetic 
analysis used in cystic ﬁ brosis NBS be improved?
Expansion of functional and clinical studies assessing disease liability of CFTR 
mutations, notably the CFTR2 project
Can the performance of cystic ﬁ brosis NBS be improved in subpopulations 
with diﬀ erent ethnic backgrounds and mutation distribution?
Further assessment of the eﬀ ectiveness of programmes not using genetic 
analysis (PAP), a wide range of studies on CFTR allelic heterogeneity, and 
identiﬁ cation of more cystic ﬁ brosis-causing mutations (CFTR2 project)
How are the positive beneﬁ ts of NBS for cystic ﬁ brosis (which can take 
decades to materialise) balanced against the negative eﬀ ect of poor positive 
predictive value and the recognition of carriers and CFSPID/CRMS
Development of a bioethical model that balances positive outcome and 
cost-eﬀ ectiveness with the eﬀ ect of carrier and CFSPID/CRMS recognition 
on families
Can cystic ﬁ brosis NBS be oﬀ ered to newborn babies and families in countries 
where this health policy has not yet been implemented?
Audit of barriers to implementation and development of strategies to 
overcome them
NBS=newborn blood spot screening. CFTR=cystic ﬁ brosis transmembrane conductance regulator. CRMS=conductance regulator-related metabolic syndrome. CFSPID=cystic 
ﬁ brosis screen-positive, inconclusive diagnosis. PAP=pancreatitis associated protein.
Table 3: Unanswered questions and future research directions
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Population carrier screening and NBS
Early diagnosis might be possible through antenatal 
cystic ﬁ brosis carrier screening. Couples are oﬀ ered 
testing for common CFTR mutations and those identiﬁ ed 
to be carriers might choose prenatal diagnosis. If parents 
opt not to terminate an aﬀ ected fetus, the opportunity for 
very early care is available. Although formal cystic ﬁ brosis 
carrier screening programmes are less widely available 
than NBS, many couples of reproductive age are oﬀ ered 
the carrier test in the USA and in some areas of Europe 
and Australia.57–59
Population carrier screening has been shown to aﬀ ect 
the performance of NBS programmes in regions who 
oﬀ er it. After several years, carrier screening might lead 
to a decrease in cystic ﬁ brosis birth prevalence, a trend 
inversely correlated with the number of carrier tests 
performed and of carrier couples detected.60 The high 
costs, organisational burden, and byproducts associated 
with NBS will be scrutinised further should the number 
of infants born with cystic ﬁ brosis decrease. Indeed, the 
European Cystic Fibrosis Society suggests a careful 
evaluation of the validity of NBS when the cystic ﬁ brosis 
incidence is less than 1 in 7000.21,61 Moreover, the 
incidence decline connected with carrier screening 
might generate an unfavourable ratio between cystic 
ﬁ brosis cases and unwanted eﬀ ects, such as false 
positives and inconclusive diagnoses.62
NBS in the context of CFTR modulator therapies
The development of therapeutic options that target the 
underlying defect in cystic ﬁ brosis has put the potential 
for early disease control into sharp perspective. These 
therapies, which target the basic pathophysiology of 
cystic ﬁ brosis, could substantially reduce morbidity and 
mortality in individuals with speciﬁ c mutations. The use 
of ivacaftor in patients carrying class III mutations has 
become the model of a personalised medicine approach 
to cystic ﬁ brosis care, and more compounds addressing 
other defects of protein synthesis or function are being 
investigated.63
Since ivacaftor is only licensed for use in infants over 
2 years of age, evidence examining the potential of ivacaftor 
in newborn infants with susceptible CFTR mutations is 
non-existent. Exploring the eﬃ  cacy of modulators in very 
young children for whom a full clinical picture of cystic 
ﬁ brosis is not yet complete might prove technically 
diﬃ  cult. Furthermore, selecting disease markers and 
endpoints will be challenging. If studies can prove that 
ivacaftor and other modulators that might be available in 
the future are beneﬁ cial and safe from birth, their impact 
on lung disease and survival rates might be strengthened. 
Moreover, preliminary reports of discontinuation of 
pancreatic enzyme therapy and partial recovery of exocrine 
pancreatic function in some patients given ivacaftor raises 
the prospect of therapies that might halt or postpone the 
loss of residual pancreatic function, which is often seen in 
the ﬁ rst months of life.64 The early and possibly 
presymptomatic use of these drugs would epitomise the 
notion of pre-emptive treatment, of which NBS is the 
archetypal example, and emphasises the signiﬁ cance of 
early diagnosis.
The future: consolidation of a complex system
Cystic ﬁ brosis NBS has been through three phases: 
discovery, assessment, and expansion. After a slow start, 
cystic ﬁ brosis NBS has expanded rapidly over the past 
decade. Data from a European Cystic Fibrosis Society 
Neonatal Screening Working Group survey showed that 
over 5 million European newborn babies and 4 million 
US newborn babies were screened for CF in 2012.11 
Furthermore, it has been estimated that worldwide over 
12 million newborn infants were screened in 2014.11 The 
use of cystic ﬁ brosis NBS increased rapidly inside Europe 
from 2000 to 2015 (ﬁ gure 1). This expansion has made 
Figure 2: Analyses and actions before and after implementation of cystic ﬁ brosis newborn blood spot 
screening programmes
CFTR=cystic ﬁ brosis transmembrane conductance regulator.  CF=cystic ﬁ brosis. *Staﬀ  in peripheral maternity 
points to be made aware of the screening procedure and able to provide correct information to parents.
Stakeholders involvement and support
Evidence-based information to policy makers
Feasibility assessment
• Cost-eﬀectiveness analysis (including birth prevalence)
• Availability of established CF care system
• Equity of performance in subpopulations
Protocol choice
• Full assessment of mutation distribution in the population
• Legislation on genetic analysis
• Geographical distribution and accuracy of sweat test laboratories
• Potential for integration into existing newborn screening 
 programmes for other diseases
Creation of a network
• Information policy for prospective parents 
• Education for maternity points*
• Communication strategies for newborn screening positives
• Involvement of Cystic Fibrosis Centres
Implementation of a newborn screening for cystic fibrosis
Quality improvement
Monitoring of:
• False negatives
• Positive predictive value
• Ratio cystic ﬁbrosis/uncertain 
 diagnoses
• Ratio cystic ﬁbrosis/carriers
• Sweat test insuﬃcient
 collections
• Eﬀectiveness of 
 communication
Follow-up of outputs
For cystic ﬁbrosis:
• Growth
• Lung disease
• Prevention of complications
• Mortality
• Early clinical trials
For uncertain diagnoses:
• Evolution to cystic ﬁbrosis
• Evolution to CFTR-related 
 disorders
Other
• Cost-eﬀectiveness
 reassessment
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early diagnosis and care possible for an unprecedented 
number of infants with cystic ﬁ brosis.
Rationalisation and optimisation of cystic ﬁ brosis NBS 
are now the focus of this public health strategy (table 3) 
as it enters a fourth phase, one of consolidation. In the 
future, programmes will need to focus both on further 
expansion in areas where cystic ﬁ brosis NBS has not yet 
been implemented and monitoring, and if necessary 
enhancement, of existing structures. Strong NBS 
structures will be in the best position to appraise and 
possibly integrate upcoming opportunities, such as next 
generation sequencing, PAP, and new therapies.
Introduction in non-screened populations
The European Cystic Fibrosis Society Neonatal Screening 
Working Group estimates that more than 2 million 
neonates born in Europe each year are not screened for 
cystic ﬁ brosis.11 Many more children are born in countries 
where cystic ﬁ brosis might be underdiagnosed and 
would beneﬁ t from a NBS programme. Providing all 
infants with the same opportunities for cystic ﬁ brosis 
NBS is good medical practice and appeals to an ethical 
principle of justice.
Several aspects of organisation and management need 
to be carefully considered when planning the introduction 
of cystic ﬁ brosis NBS in a non-screened population. Past 
experiences have shown that protocol faults, which can 
greatly aﬀ ect the performance of the system, are often 
connected with inadequate planning. Preparations for 
the programme should carefully consider a series of 
analyses and actions (ﬁ gure 2), including: the assessment 
of disease incidence, which should take into account 
resident subpopulations from diﬀ erent ethnic 
backgrounds; the brieﬁ ng of policy makers with precise 
information on the performance of screening strategies 
in their population, improvements in outcomes and 
containment of harm to families and society, and a clear 
evidence base on the eﬀ ect on cost-eﬀ ectiveness; and a 
model for language-appropriate information resources 
for parents.
Monitoring and improvement
The practice of NBS for cystic ﬁ brosis is very varied and 
dependent on local facilities and preferences. Such 
heterogeneity is not necessarily a weakness since NBS 
protocols have to be adapted to local circumstances, such 
as the ethnic composition of the population, the prevalence 
of CFTR mutations, the practice of neonatal screening for 
other diseases already in place, the discharge policy of 
maternity points (ie, when newborn babies are discharged), 
and the accessibility of skilled sweat test facilities. 
Conversely, the absence of a unique model implies that 
NBS programmes might occasionally be inadequately 
planned and under performing compared with worldwide 
acknowledged standards.19,21,61 Strategies for quality 
improvement are therefore essential. Crucial areas that 
need to be periodically assessed and if necessary improved 
are: validity and eﬀ ectiveness of the system; potential 
inequities in access to NBS and discrimination of ethnic 
subpopulations not properly covered; eﬃ  ciency of 
communication to parents from before the initial sample 
is taken through to receiving the sweat test results; results 
in terms of not only aﬀ ected infants, but also false positives, 
carriers, and infants with an unclear diagnosis; and 
middle-term and long-term clinical outcomes (ﬁ gure 2).
The ethical perspective of universal cystic ﬁ brosis NBS
NBS for cystic ﬁ brosis is clearly a valid public health 
strategy in populations in which cystic ﬁ brosis is 
common. Whether NBS can be considered a basic 
human right with a corresponding duty to provide it is 
contested at the fundamental level of whether health care 
is a right.65 Leaving this theoretical consideration aside, 
cystic ﬁ brosis NBS can be examined in ethical terms and 
this analysis used to solve some of the unanswered 
questions.56
Newborn screening for cystic ﬁ brosis follows the original 
and revised guidelines for disease screening proposed by 
Wilson and Jungner.66–68 These guidelines consider the four 
key principles of biomedical ethics: respect for autonomy, 
beneﬁ cence, non-maleﬁ cence, and justice. Examples of 
these principles from NBS for cystic ﬁ brosis include clearly 
established health beneﬁ ts of screened infants, minimising 
harm by attempting to limit the number of false positives 
and carriers detected, genetic counselling for carrier 
families, and cost-eﬀ ectiveness, which is important when 
health-care resources are limited. Further research is 
needed to minimise the number of infants with uncertain 
diagnosis after NBS. Ethical analysis could be used to help 
resolve issues related to emerging technologies (eg, the 
role of whole CFTR genome sequencing in screening), 
introduction of cystic ﬁ brosis NBS in non-screened 
populations, and discrimination of ethnic subpopulations 
not properly covered by NBS.
Cystic ﬁ brosis NBS should not be considered merely in 
terms of sensitivity and speciﬁ city, nor exclusively from a 
cost-eﬀ ectiveness viewpoint, but rather as a bioethical 
model embracing all these factors and its performance 
judged in the context of its eﬀ ect on society as a whole. 
Search strategy and selection criteria
We searched PubMed for reports published in English 
between Jan 1, 1979, and July 31, 2015, with the search terms 
“newborn screening” AND “cystic ﬁ brosis”. We also identiﬁ ed 
relevant trials and studies through hand searches of relevant 
journals (from 2000 to 2015) and abstract books of 
conference proceedings (from 1990 to 2015), including the 
European Cystic Fibrosis Conference and the North American 
Cystic Fibrosis Conference between 1990 and 2015. Selection 
for inclusion was on the basis of our skills and our perception 
of the relevance and eﬀ ect of the report on the subject of 
newborn screening for cystic ﬁ brosis.
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